Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Find generic entry opportunities
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Device for transdermal electrotransport delivery of fentanyl and sufentanil|
|Abstract:||The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl/sufentanil is provided as a water soluble salt (e.g., fentanyl hydrochloride), preferably in a hydrogel formulation, for use in an electrotransport device (10). In accordance with the present invention, a transdermal electrotransport delivered dose of fentanyl/sufentanil is provided which is sufficient to induce analgesia in (e.g., adult) human patients suffering from moderate-to-severe pain associated with major surgical procedures.|
|Inventor(s):||Southam; Mary (Menlo Park, CA), Bernstein; Keith J. (Somerville, NJ), Noorduin; Henk (Bergen op Zoom, NL)|
|Assignee:||ALZA Corporation (Mountain View, CA)|
Patent Claim Types:|
see list of patent claims
Field: Medical technology
Back Citations: 27th percentile
Forward Citations: 1st percentile
|Patent Number||Expiration Date|
|6,425,892||July 30, 2014|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Netherlands||1003273||<disabled in preview>|
|Mexico||9709644||<disabled in preview>|
|Netherlands||300235||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.